These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6616601)

  • 1. DHE retard for prophylactic therapy of migraine: efficacy and tolerability.
    Centonze V; Attolini E; Santoiemma L; Brucoli C; Macinagrossa G; Campanozzi F; Albano O
    Cephalalgia; 1983 Aug; 3 Suppl 1():179-84. PubMed ID: 6616601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Planned release dihydroergotamine in common migraine and "tension-vascular headache": multicentre clinical trial.
    Fontanari D; Perulli L; Conte F; Tambato E; Toso V; Zanetti R
    Cephalalgia; 1983 Aug; 3 Suppl 1():189-91. PubMed ID: 6352048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
    Schaerlinger B; Hickel P; Etienne N; Guesnier L; Maroteaux L
    Br J Pharmacol; 2003 Sep; 140(2):277-84. PubMed ID: 12970106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined low-dose acetylsalicylic acid and dihydroergotamine in migraine prophylaxis. A double-blind, placebo-controlled crossover study.
    Bousser MG; Chick J; Fuseau E; Soisson T; Thevenet R
    Cephalalgia; 1988 Sep; 8(3):187-92. PubMed ID: 3197098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in migraine: treatment with dihydroergotamine-retard.
    Mastrosimone F; Iaccarino C
    Cephalalgia; 1983 Aug; 3 Suppl 1():168-70. PubMed ID: 6616599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of migraine attacks through the use of dihydroergotamine.
    Neuman M; Demarez JP; Harmey JL; Le Bastard B; Cauquil J
    Int J Clin Pharmacol Res; 1986; 6(1):11-3. PubMed ID: 3514491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo].
    Hoernecke R; Doenicke A
    Med Klin (Munich); 1993 Nov; 88(11):642-8. PubMed ID: 8295604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Menstrual migraine: intermittent prophylaxis with a timed-release pharmacological formulation of dihydroergotamine.
    D'Alessandro R; Gamberini G; Lozito A; Sacquegna T
    Cephalalgia; 1983 Aug; 3 Suppl 1():156-8. PubMed ID: 6616598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroergotamine nasal spray in the treatment of acute migraine.
    Treves TA; Kuritzky A; Hering R; Korczyn AD
    Headache; 1998 Sep; 38(8):614-7. PubMed ID: 11398305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation.
    Martucci N; Manna V; Mattesi P; Troiani G; Manzoni GC; Lanfranchi M; Bono G; Micieli G
    Cephalalgia; 1983 Aug; 3 Suppl 1():151-5. PubMed ID: 6352046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators.
    Headache; 1995 Apr; 35(4):177-84. PubMed ID: 7775172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention of migraine with retard dihydroergotamine. Results of a multicenter study in 643 patients].
    Wörz R
    Fortschr Med; 1986 Nov; 104(43):838-42. PubMed ID: 3542767
    [No Abstract]   [Full Text] [Related]  

  • 13. [The long term use of dihydroergotamine (DHE-45) in migraine treatment (author's transl)].
    Miyazaki T
    Masui; 1978 Jan; 27(1):79-84. PubMed ID: 633616
    [No Abstract]   [Full Text] [Related]  

  • 14. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine.
    Boureau F; Kappos L; Schoenen J; Esperanca P; Ashford E
    Int J Clin Pract; 2000 Jun; 54(5):281-6. PubMed ID: 10954953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Double blind study of migraine therapy with etilefrine pivalate].
    Cruz A; Bühling M; Seibel K
    Arzneimittelforschung; 1985; 35(7):1086-9. PubMed ID: 2864937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Need for gastric acidification in the treatment of abdominal migraine. Results of a multicenter study on the association of Séglor retard and Vagosérine].
    Med Chir Dig; 1980; 9(6):541-4. PubMed ID: 7206866
    [No Abstract]   [Full Text] [Related]  

  • 17. Ergot pharmacology and alternative delivery systems for ergotamine derivatives.
    Goldstein J
    Neurology; 1992 Mar; 42(3 Suppl 2):45-6. PubMed ID: 1557192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care.
    Pradalier A; Lantéri-Minet M; Géraud G; Allain H; Lucas C; Delgado A
    CNS Drugs; 2004; 18(15):1149-63. PubMed ID: 15581385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.
    Silberstein S
    Expert Opin Pharmacother; 2012 Sep; 13(13):1961-8. PubMed ID: 22860628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults.
    Silvestro M; Orologio I; Tessitore A; Trojsi F; Tedeschi G; Russo A
    Expert Rev Neurother; 2024 Jun; 24(6):555-564. PubMed ID: 38655598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.